Edgewise Therapeutics, Inc. EWTX
Institutional shares held
100 Million
2.17M
calls
410K
puts
Total value of holdings
$2.68B
$58M
calls
$11M
puts
Market Cap
$1.66B
63,171,700
Shares Out.
Institutional ownership
158.57%
# of Institutions
190
We take great care to ensure that the data presented and summarized in this overview for Edgewise Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EWTX
View all-
Orbimed Advisors LLC San Diego, CA15MShares$394 Million9.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$234 Million3.32% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$158 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$153 Million1.67% of portfolio
-
Novo Holdings Hellerup, G75.55MShares$146 Million10.36% of portfolio
-
Janus Henderson Group PLC London, X04.56MShares$120 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$119 Million0.0% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.41MShares$89.5 Million6.37% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.83MShares$74.4 Million4.07% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.79MShares$73.2 Million2.68% of portfolio
Latest Institutional Activity in EWTX
Top Purchases
Top Sells
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Insider Transactions at EWTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2024
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
100,000
-87.06%
|
$2,700,000
$27.37 P/Share
|
|
Dec 30
2024
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+46.54%
|
$0
$0.18 P/Share
|
|
Dec 24
2024
|
Marc Semigran Chief Development Officer |
SELL
Open market or private sale
|
Direct |
29,709
-48.64%
|
$861,561
$29.87 P/Share
|
|
Dec 24
2024
|
Marc Semigran Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,709
+44.92%
|
$237,672
$8.94 P/Share
|
|
Oct 11
2024
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,000
+47.65%
|
$0
$0.71 P/Share
|
|
Sep 23
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
20,922
-86.55%
|
$564,894
$27.63 P/Share
|
|
Sep 23
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,922
+46.39%
|
$0
$0.71 P/Share
|
|
Sep 20
2024
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
7,162
-33.0%
|
$200,536
$28.29 P/Share
|
|
Sep 20
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
50,000
-93.89%
|
$1,400,000
$28.37 P/Share
|
|
Sep 20
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+48.43%
|
$0
$0.71 P/Share
|
|
Sep 20
2024
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
75,000
-45.3%
|
$2,100,000
$28.88 P/Share
|
|
Sep 20
2024
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+46.09%
|
$0
$0.18 P/Share
|
|
Sep 20
2024
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
125,092
-58.42%
|
$3,502,576
$28.58 P/Share
|
|
Sep 20
2024
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
96,068
+41.37%
|
$96,068
$1.93 P/Share
|
|
Sep 20
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
42,068
-73.56%
|
$1,219,972
$29.03 P/Share
|
|
Sep 20
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
42,068
+42.38%
|
$42,068
$1.93 P/Share
|
|
May 02
2024
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,157
-5.77%
|
$38,826
$18.91 P/Share
|
|
May 02
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
1,956
-37.56%
|
$35,208
$18.91 P/Share
|
|
May 02
2024
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
3,152
-17.88%
|
$56,736
$18.91 P/Share
|
|
May 02
2024
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
3,682
-15.62%
|
$66,276
$18.91 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.56M
Shares
From
9
Insiders
| Open market or private purchase | 909K shares |
|---|---|
| Exercise of conversion of derivative security | 655K shares |
Sell / Disposition
594K
Shares
From
7
Insiders
| Open market or private sale | 594K shares |
|---|